Exposure During Pregnancy
7
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
A Study of Females With CF Throughout Pregnancy and Post-partum, and Follow up of Their Offspring
Neuropsychological Development and Executive Functioning of Children Born to HIV- Infected Mothers ( NEUROPSY-HEU )
Hair Care Product Use Among Women Of Color
A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy
Biogen Multiple Sclerosis Pregnancy Exposure Registry
Evaluation of Systemic and Oral Conditions of Pregnant Women and Their Babies, With Exposure to COVID-19 Infection
Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia